Gastric Cancer Clinical Trials in Chengdu
8 recruitingChengdu, China
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
Study for AZD4360 in Participants With Advanced Solid Tumours
Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled17 locationsNCT06921928
Recruiting
Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Gastric CancerGastroesophageal-junction Cancer
AstraZeneca572 enrolled186 locationsNCT06346392
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled284 locationsNCT06764875
Recruiting
Phase 3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Esophageal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca2,130 enrolled230 locationsNCT07431281
Recruiting
Phase 2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Gastric Cancer
AstraZeneca450 enrolled100 locationsNCT04379596
Recruiting
Phase 2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca224 enrolled52 locationsNCT06219941
Recruiting
Phase 2
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
AstraZeneca175 enrolled31 locationsNCT06271837